Gene and Cell Therapy – Webinars and Online Events

Human induced pluripotent stem cells (iPSC) can renew almost indefinitely and differentiate to any adult cell in the body thus making them ideal materials for developing new cell-based therapies. The efficacy and manufacturability of these therapies critically rely on reagents such as media and surface substrates used during iPSC expansion and differentiation outcomes.

Speaking at Cell & Gene Therapy 2023, Dr. Gabriella Perell and Dr. Xi Lu from Bio-Techne, presented their talk on Biotechne’s portfolio of cGMP and animal-free reagents including iPSC expansion media, vitronectin culture substrates, small molecules, and growth factors. Dr, Perell and Dr. Lu will demonstrate the application of these reagents towards establishing an iPSC to iNK workflow.

Speaking at Cell & Gene Therapy 2023,Tracy Zhao from ACROBiosystems, presented their talk on products and services across cell therapy research and development.

Speaking at Cell and Gene Therapy 2023, Habib Malik from Bio-Techne, presented their talk on reproducible and easy-to-use immunoassay platforms.

In this webinar, we will guide you through the essential steps of the CAR T workflow while emphasizing the critical role of in-process control and quality control.

The biopharma industry has used capillary electrophoresis for many years to help improve the quality of biopharmaceuticals. Traditionally, scientists have utilized single capillaries or chips in these systems, requiring samples to be run in series.
However, a new multi-capillary system was recently launched, enabling scientists to parallel process eight samples simultaneously. Discover the impact of multi-capillary systems in the development of cell and gene therapies and therapeutic proteins.

In recent years we’ve seen a steep rise in the application of nanomedicine, particularly with the use of viral and non-viral delivery vectors for nucleic acids, for use in vaccine development and cell and gene therapy.

Our expert speaker will discuss the current market presence of CAR T cells and the market potential for cell therapy research.

Bio-Techne has extensive experience in and offers a strong and diverse portfolio for the generation, maintenance and characterization of organoids and other 3D culture systems such as spheroids.

bit.bio’s first-of-its-kind precision cellular reprogramming technology, opti-ox™, addresses the limitations of lot consistency, cell definition and scalability by controlling the precise expression of cell-fate determining genetic factors.

Speaking at Cell & Gene Therapy 2023, Kevin Holden, PhD from Synthego, presented their talk on synthesizing CRISPR guide RNAs.